X0206 3 2024-04-02 0 0001635088 Roivant Sciences Ltd. ROIV 0001635075 Ramaswamy Vivek P.O. BOX 20860 COLUMBUS OH 43220 0 0 1 0 Common Shares 53431426 D Stock Option (Right to Buy) 12.68 2026-03-31 Common Shares 21856138 D Stock Option (Right to Buy) 13.78 2026-03-31 Common Shares 1753905 D Stock Option (Right to Buy) 15.85 2026-03-31 Common Shares 5915052 D Capped Value Appreciation Rights 11.5 2026-03-31 Common Shares 11570769 D Reflects an award of stock options to purchase Common Shares that is fully vested. Reflects a fully service-vested award of capped value appreciation rights ("CVARs") that, upon achievement of the hurdle price condition based on the hurdle price reflected in column 4 of Table II above on an applicable measurement date, entitle the reporting person to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price reflected in column 4 of Table II above (such excess, the "CVAR Amount"). The CVARs will be settled in a number of Common Shares determined by dividing (i) the applicable CVAR Amount by (ii) the fair market value of a Common Share as of the applicable payment date. The reporting person became a 10% shareholder of the Issuer following the repurchase of Common Shares announced by the Issuer on April 2, 2024 and not through any transaction by the reporting person. By: /s/ Stephen Roberts, as Attorney-in-Fact for Vivek Ramaswamy 2024-04-12